Skip to main content


You are here

Remedy Pharmaceuticals Initiates Phase 2A Study of CIRARA™ in Spinal Cord Injury

Tuesday, August 18, 2015

Remedy Pharmaceuticals, a company focused on the development and commercialization of CIRARA™, a breakthrough drug for treating acute central nervous system conditions, announced that a prospective multi-center open-label pilot study of CIRARA in patients with acute traumatic cervical spinal cord injuries. 

Up to five Level I trauma centers will be involved in the trial, including University of Ohio Wexner Medical Center as Principal Site. The study’s Principal Investigator is H. Francis Farhadi, M.D., Ph.D., Clinical Assistant Professor, Department of Neurological Surgery and Director, Spinal Surgery Fellowship Program at The Ohio State University.

According to the World Health Organization, annually there are somewhere between 133,000 and 226,000 cases of spinal cord injury worldwide. There are approximately 12,000 new cases of spinal cord injury each year in the United States. Presently, over 250,000 people in the U.S. are living with a spinal cord injury.

Click here to read the entire release.